| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 0 | - |
| Operating Income | -129.6MM | -5% |
| Operating Expenses | 129.6MM | -5% |
| Net Income | -113.8MM | -4% |
| R&D | 82.2MM | -21% |
| G&A | 47.4MM | +47% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
In this article, we will be taking a look at the 30 biggest biotechnology companies in the world. If you do not want to learn about the global biotech market, head straight to the 5 Biggest Biotechnology Companies in the World. In the ever-evolving landscape of biotechnology, several companies like Novo Nordisk, Regeneron, and United […]
With the business potentially at an important milestone, we thought we'd take a closer look at Karuna Therapeutics...
Karuna Therapeutics Inc (NASDAQ:KRTX), a clinical-stage biopharmaceutical company focused on developing novel therapies for neuropsychiatric disorders, has reported an insider sale according to a recent SEC filing.
Bronte Capital, an investment management company, released its “Amalthea Fund” fourth-quarter 2023 investor letter. A copy of the same can be downloaded here. The fund lost -2.12% in December, -0.97% for the quarter, and gained 15.60% for the calendar year. Compared to that, the MSCI ACWI index had gains of 1.28%, 4.63%, and 21.92% (in $A) […]
Karuna's (KRTX) fourth-quarter 2023 earnings and revenues miss estimates. The company is set to be acquired by Bristol Myers.
Unveiling the Strengths and Challenges: A Deep Dive into Karuna Therapeutics Inc (KRTX) SWOT Analysis
Company Prepares for Potential KarXT Launch and Anticipates Bristol Myers Squibb Acquisition
BOSTON, February 22, 2024--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided a general business update.
The New York Times published an article in early February about mental health and the failure of New York City to carefully audit its program to treat mentally ill people living on the streets. When I read articles like this, it makes me think about possible related investments. Specifically, in this case, mental health stocks. It could be a drug company that’s got a treatment for mental health that’s working for patients. Another possibility is operators of mental health facilities. However, it
(Bloomberg) -- Bristol Myers Squibb sold $13 billion of bonds to help finance its acquisitions of Karuna Therapeutics Inc. and RayzeBio Inc., a deal that gathered orders exceeding $85 billion, according to a person with knowledge of the matter.Most Read from BloombergJapan Loses Its Spot as World's Third-Largest Economy as It Slips Into RecessionIsrael Quits Ceasefire Talks Over ‘Delusional’ Hamas DemandsThe Brutal Reality of Plunging Office Values Is HereTrump Eyes NATO Makeover, Hurried Peace